Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 14;42(6):487-494.
doi: 10.3760/cma.j.issn.0253-2727.2021.06.008.

[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma]

[Article in Chinese]
X Yang  1 , S Chen  1 , Y Qi  1 , X Y Xu  1 , X Guan  1 , Y C Yang  1 , Y X Liu  1 , Y H Guo  1 , W C Gong  1 , Y N Gao  1 , X H Wang  2 , W Li  2 , L F Li  2 , K Fu  3 , H L Zhang  2 , B Meng  1
Affiliations

[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma]

[Article in Chinese]
X Yang et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Objective: To screen and analyze the prognostic protein biomarkers of DLBCL, and to explore their value in the prognostic evaluation. Methods: 163 cases of confirmed DLBCLs from January 2011 to December 2016 were collected with their clinical, pathological and follow-up data, which were all from our hospital. The expression of protein markers were tested using immunohistochemical staining (IHC) . The immune phenotypes independent of the International Prognostic Index (IPI) that affect overall survival (OS) and progression-free survival (PFS) of DLBCL were explored by COX regression model, and the effect of their co-expression on the prognosis were also analyzed. Result: BCL6 negative (PFS: HR=1.652, 95%CI 1.030-2.649, P=0.037) , P53 positive (OS: HR=1.842, 95%CI 1.008-3.367, P=0.047) , and BCL2 strong positive expressions (S+) (OS: HR=2.102, 95%CI 1.249-3.537, P=0.005; PFS: HR=2.126, 95%CI 1.312-3.443, P=0.002) are adverse prognostic factors of DLBCL that are independent of IPI. BCL6(-) (PFS: HR=2.042, 95%CI 1.021-4.081, P=0.043) , P53(+) (OS: HR=3.069, 95%CI 1.244-7.569, P=0.015) and BCL2(S+) (OS: HR=2.433, 95%CI 1.165-5.082, P=0.018; PFS: HR=3.209, 95%CI 1.606-6.410, P=0.001) are adverse prognostic factors in the group of age≤60-year-old; in the group of IPI score 0-2, cases with BCL6(-) (OS: HR=2.467, 95%CI 1.322-4.604, P=0.005; PFS: HR=2.248, 95%CI 1.275-3.965, P=0.005) and BCL2(S+) (PFS: HR=2.045, 95%CI 1.119-3.735, P=0.020) have worse prognosis. The co-expression of BCL6(-) and BCL2(S+) has significant influence on prognosis of DLBCL (P=0.005 and P<0.001) , in which BCL6(+)/non-BCL2(S+) (n=86) has the best prognosis[3-year-OS (71.6±4.9) %, 3-year-PFS (67.0±5.1) %], and BCL6(-)/BCL2(S+) (n=10) has the worst prognosis[3-year-OS (20.0±12.6) %, 3-year-PFS (10.0±9.5) %]; the co-expression of BCL6(-) and P53(+) has no significant influence on prognosis (P=0.061 and P=0.089) , however, those cases with BCL6(+)/P53(-) (n=98) often get better prognosis[3-year-OS (70.6±4.7) %, 3-year-PFS (64.6±4.9) %] than others; the co-expression of P53(+) and BCL2(S+) has significant influence on prognosis of DLBCL (P<0.001 and P<0.001) , and P53(+)/BCL2(S+) (n=5) has the worst prognosis (3-year-OS and 3-year-PFS are both 0) ; BCL2(S+) cases get shorter OS and PFS, regardless of the expression of BCL6 and P53. Conclusion: The expression and co-expression of BCL6 negative, P53 positive and BCL2(S+) have certain value in the prognostic evaluation of DLBCL, especially in the group of age≤60-year-old and IPI score 0-2.

目的： 筛选并分析与弥漫大B细胞淋巴瘤（DLBCL）预后相关的免疫表型，探究其预后价值。 方法： 选取天津医科大学肿瘤医院2011年1月至2016年12月收治的163例DLBCL患者，免疫组织化学染色检测DLBCL常见免疫表型，COX模型探索独立于国际预后指数（IPI）影响总生存（OS）与无进展生存（PFS）的免疫表型，并分析其两两联合表达对预后的影响。 结果： 多因素分析显示BCL6阴性（PFS：HR=1.652，95%CI 1.030~2.649，P=0.037）、P53阳性（OS：HR=1.842，95%CI 1.008~3.367，P=0.047）、BCL2强阳性（OS：HR=2.102，95%CI 1.249~3.537，P=0.005；PFS：HR=2.126，95%CI 1.312~3.443，P=0.002）是DLBCL中独立于IPI的预后不良因素。亚组分析显示，在年龄≤60岁组患者中BCL6阴性（PFS：HR=2.042，95%CI 1.021~4.081，P=0.043）、P53阳性（OS：HR=3.069，95%CI 1.244~7.569，P=0.015）和BCL2强阳性（OS：HR=2.433，95%CI 1.165~5.082，P=0.018；PFS：HR=3.209，95%CI 1.606~6.410，P=0.001）对预后影响显著；在IPI 0~2分亚组患者中，BCL6阴性（OS：HR=2.467，95%CI 1.322~4.604，P=0.005；PFS：HR=2.248，95%CI 1.275~3.965，P=0.005）和BCL2强阳性（PFS：HR=2.045，95%CI 1.119~3.735，P=0.020）对预后影响显著。BCL6和BCL2强阳性的联合表达与DLBCL的预后相关（P=0.005和P<0.001），BCL6阳性/BCL2非强阳性（86例）预后最好[3年OS率（71.6±4.9）%，3年PFS率（67.0±5.1）%]，BCL6阴性/BCL2强阳性（10例）预后最差[3年OS率（20.0±12.6）%，3年PFS率（10.0±9.5）%]；BCL6、P53的联合表达与DLBCL的预后差异无统计学意义（P=0.061和P=0.089），但生存曲线显示BCL6阳性/P53阴性的病例（98例）预后较好[3年OS率（70.6±4.7）%，3年PFS率（64.6±4.9）%]；BCL2强阳性、P53的联合表达与DLBCL的预后显著相关（P<0.001和P<0.001），BCL2强阳性/P53阳性的病例（5例）预后最差（3年OS率和PFS率均为0）；无论BCL6与P53表达如何，BCL2强阳性的病例预后均比非强阳性病例差。 结论： BCL6阴性、P53阳性、BCL2强阳性三种免疫表型单独及联合表达对DLBCL尤其是年龄≤60岁和IPI 0~2分患者的预后预测具有一定价值。.

Keywords: BCL2; BCL6; Diffuse large B-cell lymphoma; P53; Prognosis.

PubMed Disclaimer

Figures

图1
图1. 不同BCL6、P53和BCL2表达分组弥漫大B细胞淋巴瘤患者总生存（A～C）与无进展生存（D～F）曲线
A、D：BCL6表达；B、E：P53表达；C、F：BCL2表达
图2
图2. 不同BCL6、P53和BCL2两两联合表达弥漫大B细胞淋巴瘤患者总生存（A～C）与无进展生存（D～F）曲线
A、D：BCL6、BCL2联合表达；B、E：BCL6、P53联合表达；C、F：BCL2、P53联合表达
See this image and copyright information in PMC

References

    1. Gascoyne RD, Campo E, Jeffe ES, et al. Diffuse large B-cell lymphoma, NOS, in Swerdlow SH, Campo E, Harris NL, et al (eds): WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed[M] Lyon: IARC; 2017. pp. 291–297.
    1. Li L, Li Y, Que X, et al. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis[J] Sci Rep. 2018;8(1):6267. doi: 10.1038/s41598-018-24631-5. - DOI - PMC - PubMed
    1. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma[J] N Engl J Med. 1993;329(14):987–994. doi: 10.1056/NEJM199309303291402. - DOI - PubMed
    1. Teoh CS, Lee SY, Chiang SK, et al. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience[J] Asian Pac J Cancer Prev. 2018;19(5):1229–1236. doi: 10.22034/APJCP.2018.19.5.1229. - DOI - PMC - PubMed
    1. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas[J] Am J Surg Pathol. 2000;24(6):846–852. doi: 10.1097/00000478-200006000-00010. - DOI - PubMed

MeSH terms

Substances